95 SEQUENTIAL USE OF TEMSIROLIMUS (TEM) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT